Angiotensin II mediates systemic rebound hypertension after cessation of prostacyclin infusion in sheep

Journal of Applied Physiology

Volumn 85, Issue 2, 1998, Pages 731-737

  Robbins, Ivan M ^a   Cuiper, Leslie L ^a   Stein, C Michael ^a   Wood, Alastair J J ^a   He, Huai B ^a   Parker, Richard ^a   Christman, Brian W ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

Epoprostenol; Norepinephrine; Prostaglandin I2; Pulmonary hypertension; Renin

Indexed keywords

2 ETHYL 5,7 DIMETHYL 3 [4 [2 (2H TETRAZOL 5 YL)PHENYL]BENZYL]IMIDAZO[4,5 B]PYRIDINE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; CATECHOLAMINE; NORADRENALIN; PROSTACYCLIN; RENIN;

ADRENERGIC SYSTEM; ALPHA ADRENERGIC RECEPTOR BLOCKING; ANIMAL MODEL; ARTICLE; BLOOD VESSEL TONE; DYSPNEA; FATIGUE; HEART OUTPUT; MEAN ARTERIAL PRESSURE; NONHUMAN; PLASMA RENIN ACTIVITY; PRESSOR RESPONSE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SHEEP;

EID: 0031880214     PISSN: 87507587     EISSN: None     Source Type: Journal    
DOI: 10.1152/jappl.1998.85.2.731     Document Type: Article

References (37)

1. Badesch, D. B., E. C. Orton, L. M. Zapp, J. Y. Westcott, J. Hester, N. F. Voelkel, and K. R. Stenmark. Decreased arterial wall prostaglandin production in neonatal calves with severe chronic pulmonary hypertension. Am. J. Respir. Cell Mol. Biol. 1: 489-498, 1989.
2. Barst, R. J., L. J. Rubin, W. A. Long, M. D. McGoon, S. Rich, D. B. Badesch, B. M. Groves, V. F. Tapson, R. C. Bourge, B. H. Brundage, S. K. Koerner, D. Langleben, C. A. Keller, S. Murali, B. F. Uretsky, L. M. Clayton, M. M. Jöbsis, S. D. Blackburn, Jr., D. Shortino, and J. W. Crow. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for the treatment of pulmonary hypertension. N. Engl. J. Med. 334: 296-301, 1996.
3. Barst, R. J., L. J. Rubin, M. D. McGoon, E. J. Caldwell, W. A. Long, and P. S. Levy. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann. Intern. Med. 121: 409-415, 1994.
4. Barst, R. J., S. A. Stalcup, C. N. Steeg, J. C. Hall, M. F. Frosolono, A. E. Cato, and R. B. Mellins. Relation of arachidonate metabolites to abnormal control of the pulmonary circulation in a child. Am. Rev. Respir. Dis. 131: 171-177, 1985.
5. Belch, J. J., P. Newman, J. K. Drury, H. Capell, P. Leiberman, W. B. James, C. D. Forbes, and C. R. Prentice. Successful treatment of Raynaud's syndrome with prostacyclin. Thromb. Haemost. 45: 255-256, 1981.
6. Blankestijn, P. J., A. J. Man in't Veld, J. Tulen, A. H. van den Meiracker, F. Boomsma, P. Moleman, H. J. Ritsema Van Eck, F. H. Derkx, P. Mulder, S. J. Lamberts, and M. A. Schalekamp. Support for the adrenaline-hypertension hypothesis: 18 hour pressor effect after 6 hours of adrenaline infusion. Lancet 2: 1386-1389, 1988.
7. Brown, M. J., D. C. Brown, and M. B. Murphy. Hypokalemia from β2-receptor stimulation by circulating epinephrine. N. Engl. J. Med. 309: 1414-1419, 1983.
8. Brown, M. J., and I. Macquin. Is adrenaline the cause of essential hypertension? Lancet 2: 1079-1081, 1981.
9. Christman, B. W., C. D. McPherson, J. H. Newman, G. A. King, G. R. Bernard, B. M. Groves, and J. E. Loyd. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N. Engl. J. Med. 327: 70-75, 1992.
10. 2. J. Appl. Physiol. 80: 191-197, 1996.
11. 2) in the circulation of the dog. Br. J. Pharmacol. 63: 414P-415P, 1978.
12. El Tahir, K. E., K. I. Williams, and D. J. Betteridge. Differences in the stability of prostacyclin in human, rabbit and rat plasma. Prostaglandins Leukot. Med. 10: 109-114, 1983.
13. Feddersen, K., M. Aurell, K. Delin, J. Häggendal, C. Arén, and K. Rådegran. Effects of cardiopulmonary bypass and prostacyclin on plasma catecholamines, angiotensin II and arginine-vasopressin. Acta Anaesthesiol. Scand. 29: 224-230, 1985.
14. Fellows, I. W., T. Bennett, and I. A. MacDonald. The effect of adrenaline upon cardiovascular and metabolic functions in man. Clin. Sci. (Colch.) 69: 215-222, 1985.
15. Floras, J. S. Epinephrine and the genesis of hypertension. Hypertension 19: 1-18, 1992.
16. Frölich, J. C., J. W. Hollifield, A. M. Michelakis, B. S. Vesper, J. P. Wilson, P. G. Shand, H. J. Seyberth, W. H., Frölich, and J. A. Oates. Reduction of plasma renin activity by inhibition of fatty acid cyclooxygenase in human subjects. Circ. Res. 44: 781-787, 1979.
17. He, H. B., R. J. Deegan, M. Wood, and A. J. J. Wood. Optimization of HPLC assay for catecholamines: determination of ideal mobile phase composition and elimination of species-dependent differences in extraction recovery of DHBA. J. Chromatogr. A 574: 213-218, 1992.
18. Higenbottam, T. The place of prostacyclin in the clinical management of primary pulmonary hypertension. Am. Rev. Respir. Dis. 136: 782-785, 1987.
19. Higenbottam, T. W., D. Spiegelhalter, J. P. Scott, V. Fuster, A. T. Dinh-Xuan, N. Cain, and J. Wallwork. Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension. Br. Heart J. 70: 366-370, 1993.
20. Higenbottam, T. W., F. Wells, D. Wheeldon, and J. Wallwork. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet 1: 1046-1047, 1984.
21. Jones, K., T. Higenbottam, and J. Wallwork. Pulmonary vasodilation with prostacyclin in primary and secondary pulmonary hypertension. Chest 96: 784-789, 1989.
22. Jones, D. K., T. W. Higenbottam, and J. Wallwork. Treatment of primary pulmonary hypertension with intravenous epoprostenol (prostacyclin). Br. Heart J. 57: 270-278, 1987.
23. Kane, D. W., T. Tesauro, and J. H. Newman. Adrenergic modulation of the pulmonary circulation during strenuous exercise in sheep. Am. Rev. Respir. Dis. 147: 1233-1238, 1993.
24. Majewski, H., and M. J. Rand. Prejunctional β-adrenoceptors and hypertension: a hypothesis revisited. Trends Pharmacol. Sci. 5: 500-502, 1984.
25. Miyamori, I., G. A. FitzGerald, M. J. Brown, and P. J. Lewis. Prostacyclin stimulates the renin angiotensin aldosterone system in man. J. Clin. Endocrinol. Metab. 49: 943-944, 1979.
26. Nezu, M., Y. Miura, M. Adachi, S. Kimura, S. Toriyabe, Y. Ishizuka, H. Ohashi, T. Sugawara, M. Takahashi, T. Noshiro, and K. Yoshinaga. The effects of epinephrine on norepinephrine release in essential hypertension. Hypertension 7: 187-195, 1985.
27. Olson, R. D., M. L. Skoglund, A. S. Nies, and J. G. Gerber. Prostaglandins mediate the macula densa stimulated renin release. Adv. Prostaglandin Thromboxane Leukot. Res. 7: 1135-1137, 1980.
28. Patrono, C., P. Rancesco, G. Ciabattoni, P. Patrignani, A. Maseri, S. Chierchia, B. A. Peskar, G. A. Cinotti, B. M. Simonetti, and A. Pierucci. Evidence for a direct stimulatory effect of prostacyclin on renin release in man. J. Clin. Invest. 69: 231-239, 1982.
29. Perkett, E. A., K. L. Brigham, and B. Meyrick. Continuous air embolization into sheep causes sustained pulmonary hypertension and increased pulmonary vasoreactivity. Am. J. Pathol. 132: 444-454, 1988.
30. Rädegran, K., C. Arén, and A. C. Teger-Nilsson. Prostacyclin infusion during extracorporeal circulation for coronary bypass. J. Thorac. Cardiovasc. Surg. 83: 205-211, 1982.
31. Rubin, L. J., J. Mendoza, M. Hood, M. McGoon, R. Barst, W. B. Williams, J. H. Diehl, J. Crow, and W. Long. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann. Intern. Med. 112: 485-491, 1990.
32. Schalekamp, M. A., H. H. Vincent, and A. J. Man in't Veld. Adrenaline, stress, and hypertension. Lancet 1: 362, 1983.
33. Stein, M., R. Deegan, H. B. He, and A. J. J. Wood. Beta adrenergic receptor mediated release of norepinephrine in the human forearm. Clin. Pharmacol. Ther. 54: 58-64, 1993.
34. Swartz, R. D., W. Flamenbaum, A. Dubrow, J. C. Hall, J. W. Crow, and A. Cato. Epoprostenol during high risk hemodialysis: preventing further bleeding complications. J. Clin. Pharmacol. 28: 818-825, 1988.
35. Szczeklik, A., R. J. Gryglewski, R. Nizankowski, P. Skawinski, P. Gluszko, and R. Korbut. Prostacyclin therapy in peripheral arterial disease. Thromb. Res. 19: 191-199, 1980.
36. 2) in 108 patients with ischemic peripheral vascular disease. Prostaglandins 39: 657-664, 1990.
37. Workman, R. J., C. R. Sussman, D. W. Burkitt, and G. W. Liddle. Circulating levels of angiotensin I measured by radioimmunoassay in hypertensive subjects. J. Lab. Clin. Med. 93: 847-56, 1979.